We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

18 hedge funds and large institutions have $498K invested in Titan Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

6% more funds holding

Funds holding: 17 → 18 (+1)

0.03% more ownership

Funds ownership: 0.33% → 0.35% (+0.03%)

21% less capital invested

Capital invested by funds: $633K → $498K (-$135K)

Holders
18
Holders Change
+1
Holders Change %
+5.88%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$33.3K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$12.8K
3
TSS
Two Sigma Securities
New York
+$10.5K
4
JP Morgan Chase
JP Morgan Chase
New York
+$54
5
Renaissance Technologies
Renaissance Technologies
New York
+$54

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$19.2K
2
Group One Trading
Group One Trading
Illinois
-$54

TTNP Hedge Fund Activity: Q3 2023 in Review

18 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q3 2023, worth a combined $498K — down 21% from $633K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new TTNP positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $33.3K. The largest seller was Citadel Advisors, exiting entirely with an estimated $19.2K sold.

  • 18 institutional investors held Titan Pharmaceuticals (TTNP) as of Q3 2023, up from 17 in Q2 2023.
  • Funds reported $498K of Titan Pharmaceuticals stock for Q3 2023, down 21% quarter-over-quarter.
  • 2 funds opened new Titan Pharmaceuticals positions in Q3 2023 and 1 closed out, a net change of +1 holder.
  • The largest Titan Pharmaceuticals buyer in Q3 2023 was Susquehanna International Group, an estimated $33.3K added.
  • The largest Titan Pharmaceuticals seller in Q3 2023 was Citadel Advisors, an estimated $19.2K sold.

Based on aggregated 13F filings for Q3 2023.